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therapy and the monotherapy. However, when the unob-
served selectivity was also adjusted using the switching
regression model, the combined therapy was less expen-
sive (at 90% CI) in both the treated population (TT) and
the general population (ATE). The TT was even less than
ATE and the marginal savings would be $3150 annually.
CONCLUSIONS: Given the combined therapy’s clinical
beneﬁt shown in previous studies, it is the dominant long-
term asthma-control therapy in the studied population.
The difference in ATE and TT indicates that the combined
therapy was given to patients whose health status could
be improved the most by it.
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OBJECTIVES: To assess the utilization and costs for
medical resources and pharmacotherapy among patients
with asthma in a state Medicaid population. METHODS:
Outpatient, hospital and emergency department (ED)
claims with a primary ICD-9 code for asthma (493.XX)
dated between January 1 through December 31, 1999
were extracted from a state Medicaid claims database.
Unique recipient identiﬁers obtained from these claims
were then used to extract asthma-related prescription
claims. Medicaid reimbursements were used to calculate
costs for outpatient, ED and prescription drug use, and
1999 Medicare DRG reimbursement amounts provided
by the Centers for Medicare and Medicaid Services
(CMS) were used to calculate hospital costs. Based on the
pharmacotherapy received, recipients were classiﬁed into
one of four categories: 1) short-acting beta-agonist use
only; 2) use of combination therapy without inhaled anti-
inﬂammatory medications; 3) use of any inhaled anti-
inﬂammatory therapy (inhaled corticosteroids, cromolyn,
or nedocromil); or 4) no prescription claims for asthma-
related medications. RESULTS: Overall asthma preva-
lence was 17.7/1000 Medicaid recipients. Of the 6051
recipients identiﬁed with asthma, 20.4% (n = 1233)
received short-acting beta-agonist therapy only, 34.8% 
(n = 2108) received combination therapy without 
inhaled anti-inﬂammatory drugs, 35.9% (n = 2170)
received at least one inhaled anti-inﬂammatory drug, and
8.9% (n = 540) had no prescription claims for asthma-
related medications. The hospitalization rate was 21 hos-
pitalizations/10,000 recipients at a mean cost of $3737
(SD = $1322) per visit per recipient (pvpr). The rates of
outpatient and ED use were 21 outpatient visits/1000
recipients, and 69 ED visits/10,000 recipients. The mean
cost pvpr for outpatient and ED use was $54 (SD = $72)
and $101 (SD = $126), respectively. The total asthma-
related expenditures to Medicaid were: $2,690,777 
for hospitalizations; $236,857 for ED use; $589,878 for 
outpatient use; and $1,813,240 for prescription use. 
CONCLUSIONS: Asthma is responsible for a substantial
economic burden to Medicaid, with hospital use account-
ing for most of the dollars.
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OBJECTIVES: Asthma patients’ lack of adherence to
inhaled corticosteroids (IC) contributes to treatment
failure and over $6.2 billion in associated costs. In disease
states such as hypertension, adherence rates ≥80% are
related to clinical success. Similar adherence rates for IC
in asthma patients have not yet been determined. This
study was designed to assess the relationship between IC
adherence rate and Total Medical and Drug Costs
(TMDC). METHODS: Data were from a commercial,
integrated pharmacy/medical claims database. Patients
ranging from 4 to 55 years with at least 2 claims for an
IC, a 120-day beneﬁt history, and a 360-day continuous
enrollment were included. Patients were excluded if they
were also coded for non-asthma-related pulmonary dis-
eases. Age, gender, and concomitant drug/disease infor-
mation were collected. The adherence rate was deﬁned as
[Total days supply of IC/(last RX date less ﬁrst RX date
+ last days supply)]. TMDC included drug, hospital,
physician visit and lab costs. The number of Disease
Related Events (DRE) was also determined. ANOVA or
equivalent tests, along with multiple regression tech-
niques were used to test hypotheses. RESULTS: Six
hundred forty-three patients were identiﬁed. The mean
age was 30.5 ± 15.8, with 43.5% males. We classiﬁed
8.5% of patients as 80–99% adherent, 8.2% between
60–79% adherent, 14.9% between 40–59% adherent,
and 70.6% of patients were 39% adherent. There was no
signiﬁcant difference in the TMDC among adherence
quintiles. The regression demonstrated a statistically sig-
niﬁcant correlation (r = 0.76) between age (p < 0.0001),
number of medications (p < 0.0001), co-morbidities 
(p < 0.0001), use of budesonide inhaler (p = 0.0081) or
long-acting beta agonists (p = 0.0017) against the log 
of TMDC. There were no items inversely correlated to
TMDC. There was no difference in DRE between patients
<80% or ≥80% adherent. (c2 = 0.3511, 1 d.f., p =
0.5535). CONCLUSION: Based on this study, there was
not signiﬁcant linear correlation between adherence to IC
and TMDC.
